



hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to:

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

PATENT  
Attorney Docket No.: 019957-011213US  
Client Ref. No.: NEO00018C2  
Customer No.: 20350

On March 21, 2005

TOWNSEND and TOWNSEND and CREW LLP

By: Jo Ann Honcik Dallara  
Jo Ann Honcik Dallara

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re application of:

PAULSON *et al.*

Application No.: 10/081,455

Filed: February 21, 2002

For: PRACTICAL *IN VITRO*  
SIALYLATION OF RECOMBINANT  
GLYCOPROTEINS

Confirmation No. 3039

Examiner: Rao, Manjunath N.

Art Unit: 1652

COMMUNICATION UNDER

37 C.F.R. §§ 1.821-1.825

AND

AMENDMENT

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

In response to the request to comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures, 37 C.F.R. §§ 1.821-1.825, that accompanied the Office Action, mailed October 19, 2004, Applicants submit that the computer-readable form in the instant application is identical with the Sequence Listing submitted for Application No. 09/007,741, filed August 27, 1999. In accordance with 37 C.F.R. § 1.821(e), please use the computer-readable form filed in Application No. 09/007,741 as the computer-readable form for the instant application. The information in the paper copy of the

Appl. No. 10/081,456  
Amdt. dated March 21, 2005  
Reply to Office Action of October 19, 2004

PATENT

Sequence Listing enclosed herewith is identical to that which is in the computer readable form, as required under 37 C.F.R. § 1.821(f).

It is understood that the Patent and Trademark Office will make the necessary changes in application number and filing date for the computer-readable form that will be used for the instant application.

Please amend the specification in adherence with 37 C.F.R. §§ 1.821-1.825 as follows.

**Amendments to the Specification** begin on page 3 of this paper.

**Remarks** begin on page 4 of this paper.